“The Trump administration is considering bypassing normal US regulatory standards to fast-track an experimental coronavirus vaccine from the UK for use in America ahead of the presidential election,” the Financial Times reports.
“One option being explored to speed up the availability of a vaccine would involve the US Food and Drug Administration awarding ’emergency use authorisation’ in October to a vaccine being developed in a partnership between AstraZeneca and Oxford university, based on the results from a relatively small UK study if it is successful.”
Save to Favorites